Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Regulation of IGF-1 by IGFBP3 and IGFBP5 during odontoblast differentiation in mice.

Aizawa C, Saito K, Ohshima H.

J Oral Biosci. 2019 Aug 7. pii: S1349-0079(19)30070-2. doi: 10.1016/j.job.2019.07.001. [Epub ahead of print]

PMID:
31400542
2.

Delayed childhood neurodevelopment and neurosensory alterations in the second year of life in a prospective cohort of ZIKV-exposed children.

Nielsen-Saines K, Brasil P, Kerin T, Vasconcelos Z, Gabaglia CR, Damasceno L, Pone M, Abreu de Carvalho LM, Pone SM, Zin AA, Tsui I, Salles TRS, da Cunha DC, Costa RP, Malacarne J, Reis AB, Hasue RH, Aizawa CYP, Genovesi FF, Einspieler C, Marschik PB, Pereira JP, Gaw SL, Adachi K, Cherry JD, Xu Z, Cheng G, Moreira ME.

Nat Med. 2019 Aug;25(8):1213-1217. doi: 10.1038/s41591-019-0496-1. Epub 2019 Jul 8.

PMID:
31285631
3.

Neurodevelopment in Infants Exposed to Zika Virus In Utero.

Lopes Moreira ME, Nielsen-Saines K, Brasil P, Kerin T, Damasceno L, Pone M, Carvalho LMA, Pone SM, Vasconcelos Z, Ribeiro IP, Zin AA, Tsui I, Adachi K, Gaw SL, Halai UA, Salles TS, da Cunha DC, Bonaldo MC, Raja Gabaglia C, Guida L, Malacarne J, Costa RP, Gomes SC Jr, Reis AB, Soares FVM, Hasue RH, Aizawa CYP, Genovesi FF, Aibe M, Einspieler C, Marschik PB, Pereira JP Jr, Portari EA, Janzen C, Cherry JD.

N Engl J Med. 2018 Dec 13;379(24):2377-2379. doi: 10.1056/NEJMc1800098. No abstract available.

4.

The use of platelet-rich fibrin with platelet-rich plasma support meniscal repair surgery.

Kemmochi M, Sasaki S, Takahashi M, Nishimura T, Aizawa C, Kikuchi J.

J Orthop. 2018 May 15;15(2):711-720. doi: 10.1016/j.jor.2018.05.006. eCollection 2018 Jun.

5.

Conventional physical therapy and physical therapy based on reflex stimulation showed similar results in children with myelomeningocele.

Aizawa CY, Morales MP, Lundberg C, Moura MC, Pinto FC, Voos MC, Hasue RH.

Arq Neuropsiquiatr. 2017 Mar;75(3):160-166. doi: 10.1590/0004-282X20170009.

6.

Patients with autosomal dominant spinocerebellar ataxia have more risk of falls, important balance impairment, and decreased ability to function.

Aizawa CY, Pedroso JL, Braga-Neto P, Callegari MR, Barsottini OG.

Arq Neuropsiquiatr. 2013 Aug;71(8):508-11. doi: 10.1590/0004-282X20130094.

7.

Antihypertensive effect of gamma-amino butyric acid enriched soy products in spontaneously hypertensive rats.

Shizuka F, Kido Y, Nakazawa T, Kitajima H, Aizawa C, Kayamura H, Ichijo N.

Biofactors. 2004;22(1-4):165-7.

PMID:
15630275
8.

Cloning of the gene coding for Staphylococcus intermedius exfoliative toxin and its expression in Escherichia coli.

Terauchi R, Sato H, Endo Y, Aizawa C, Maehara N.

Vet Microbiol. 2003 Jun 24;94(1):31-8.

PMID:
12742713
9.

Isolation of exfoliative toxin from Staphylococcus intermedius and its local toxicity in dogs.

Terauchi R, Sato H, Hasegawa T, Yamaguchi T, Aizawa C, Maehara N.

Vet Microbiol. 2003 Jun 24;94(1):19-29.

PMID:
12742712
10.

Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K).

Watanabe I, Hagiwara Y, Kadowaki SE, Yoshikawa T, Komase K, Aizawa C, Kiyono H, Takeda Y, McGhee JR, Chiba J, Sata T, Kurata T, Tamura S.

Vaccine. 2002 Oct 4;20(29-30):3443-55.

PMID:
12297389
11.

Methylphenidate hydrochloride for excessive daytime sleepiness in a patient with myotonic dystrophy.

Miyamoto T, Miyamoto M, Suga T, Aizawa C, Takekawa H, Hirata K.

Psychiatry Clin Neurosci. 2002 Jun;56(3):271-2.

12.

Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines.

Asahi Y, Yoshikawa T, Watanabe I, Iwasaki T, Hasegawa H, Sato Y, Shimada S, Nanno M, Matsuoka Y, Ohwaki M, Iwakura Y, Suzuki Y, Aizawa C, Sata T, Kurata T, Tamura S.

J Immunol. 2002 Mar 15;168(6):2930-8.

13.

Onjisaponins, from the root of Polygala tenuifolia Willdenow, as effective adjuvants for nasal influenza and diphtheria-pertussis-tetanus vaccines.

Nagai T, Suzuki Y, Kiyohara H, Susa E, Kato T, Nagamine T, Hagiwara Y, Tamura S, Yabe T, Aizawa C, Yamada H.

Vaccine. 2001 Sep 14;19(32):4824-34.

PMID:
11535335
14.

Immune responses and protection in different strains of aged mice immunized intranasally with an adjuvant-combined influenza vaccine.

Asanuma H, Hirokawa K, Uchiyama M, Suzuki Y, Aizawa C, Kurata T, Sata T, Tamura S.

Vaccine. 2001 Jul 16;19(28-29):3981-9.

PMID:
11427274
15.

Collagen minipellet as a controlled release delivery system for tetanus and diphtheria toxoid.

Higaki M, Azechi Y, Takase T, Igarashi R, Nagahara S, Sano A, Fujioka K, Nakagawa N, Aizawa C, Mizushima Y.

Vaccine. 2001 Apr 30;19(23-24):3091-6.

PMID:
11312003
16.

Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine.

Hagiwar Y, Tsuji T, Iwasaki T, Kadowaki S, Asanuma H, Chen Z, Komase K, Suzuki Y, Aizawa C, Kurata T, Tamura S.

Vaccine. 2001 Feb 28;19(15-16):2071-9.

PMID:
11228379
17.

Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain.

Hagiwara Y, Iwasaki T, Asanuma H, Sato Y, Sata T, Aizawa C, Kurata T, Tamura S.

Vaccine. 2001 Feb 8;19(13-14):1652-60.

PMID:
11166888
18.

Change in gelatin content of vaccines associated with reduction in reports of allergic reactions.

Nakayama T, Aizawa C.

J Allergy Clin Immunol. 2000 Sep;106(3):591-2. No abstract available.

PMID:
10984383
19.

Cloning of the gene coding for Staphylococcus hyicus exfoliative toxin B and its expression in Escherichia coli.

Watanabe T, Sato H, Hatakeyama Y, Matsuzawa T, Kawai M, Aizawa C, Danbara H, Maehara N.

J Bacteriol. 2000 Jul;182(14):4101-3.

20.

Chromosomal and extrachromosomal synthesis of exfoliative toxin from Staphylococcus hyicus.

Sato H, Watanabe T, Higuchi K, Teruya K, Ohtake A, Murata Y, Saito H, Aizawa C, Danbara H, Maehara N.

J Bacteriol. 2000 Jul;182(14):4096-100.

21.

Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation.

Kadowaki S, Chen Z, Asanuma H, Aizawa C, Kurata T, Tamura S.

Vaccine. 2000 Jun 15;18(25):2779-88.

PMID:
10812219
22.

Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein.

Chen Z, Yoshikawa T, Kadowaki S, Hagiwara Y, Matsuo K, Asanuma H, Aizawa C, Kurata T, Tamura S.

J Gen Virol. 1999 Oct;80 ( Pt 10):2559-64.

PMID:
10573147
23.

Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine.

Hagiwara Y, Komase K, Chen Z, Matsuo K, Suzuki Y, Aizawa C, Kurata T, Tamura S.

Vaccine. 1999 Jul 16;17(22):2918-26.

PMID:
10438064
24.

New exfoliative toxin produced by a plasmid-carrying strain of Staphylococcus hyicus.

Sato H, Watanabe T, Murata Y, Ohtake A, Nakamura M, Aizawa C, Saito H, Maehara N.

Infect Immun. 1999 Aug;67(8):4014-8.

25.

Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs.

Chen Z, Matsuo K, Asanuma H, Takahashi H, Iwasaki T, Suzuki Y, Aizawa C, Kurata T, Tamura S.

Vaccine. 1999 Feb 26;17(7-8):653-9.

PMID:
10067670
27.

Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza.

Chen Z, Sahashi Y, Matsuo K, Asanuma H, Takahashi H, Iwasaki T, Suzuki Y, Aizawa C, Kurata T, Tamura S.

Vaccine. 1998 Oct;16(16):1544-9.

PMID:
9711802
29.

Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine.

Komase K, Tamura S, Matsuo K, Watanabe K, Hattori N, Odaka A, Suzuki Y, Kurata T, Aizawa C.

Vaccine. 1998 Jan-Feb;16(2-3):248-54.

PMID:
9607038
30.

Enhancement of immune response to intranasal influenza HA vaccine by microparticle resin.

Higaki M, Takase T, Igarashi R, Suzuki Y, Aizawa C, Mizushima Y.

Vaccine. 1998 Apr;16(7):741-5.

PMID:
9562695
31.

Antibody-forming cells in the nasal-associated lymphoid tissue during primary influenza virus infection.

Tamura S, Iwasaki T, Thompson AH, Asanuma H, Chen Z, Suzuki Y, Aizawa C, Kurata T.

J Gen Virol. 1998 Feb;79 ( Pt 2):291-9.

PMID:
9472613
32.

Effect of dual-subtype vaccine against feline immunodeficiency virus infection.

Hohdatsu T, Okada S, Motokawa K, Aizawa C, Yamamoto JK, Koyama H.

Vet Microbiol. 1997 Nov;58(2-4):155-65.

PMID:
9453127
33.

Effects of frequent intranasal administration of adjuvant-combined influenza vaccine on the protection against virus infection.

Tamura S, Yajima A, Hatori E, Tamura S, Asanuma H, Suzuki Y, Aizawa C, Kurata T.

Vaccine. 1997 Nov;15(16):1784-90.

PMID:
9364684
34.

Isolation and characterization of mouse nasal-associated lymphoid tissue.

Asanuma H, Thompson AH, Iwasaki T, Sato Y, Inaba Y, Aizawa C, Kurata T, Tamura S.

J Immunol Methods. 1997 Mar 28;202(2):123-31.

PMID:
9107301
36.

Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein.

Tamura S, Miyata K, Matsuo K, Asanuma H, Takahashi H, Nakajima K, Suzuki Y, Aizawa C, Kurata T.

J Immunol. 1996 May 15;156(10):3892-900.

PMID:
8621928
37.

Complete inhibition of human immunodeficiency virus Gag myristoylation is necessary for inhibition of particle budding.

Morikawa Y, Hinata S, Tomoda H, Goto T, Nakai M, Aizawa C, Tanaka H, Omura S.

J Biol Chem. 1996 Feb 2;271(5):2868-73.

38.

Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin.

Hashigucci K, Ogawa H, Ishidate T, Yamashita R, Kamiya H, Watanabe K, Hattori N, Sato T, Suzuki Y, Nagamine T, Aizawa C, Tamura S, Kurata T, Oya A.

Vaccine. 1996 Feb;14(2):113-9.

PMID:
8852406
39.

Characterization of mouse nasal lymphocytes isolated by enzymatic extraction with collagenase.

Asanuma H, Inaba Y, Aizawa C, Kurata T, Tamura S.

J Immunol Methods. 1995 Nov 16;187(1):41-51.

PMID:
7490457
40.

Immune response in mice infected with the attenuated Japanese encephalitis vaccine strain SA14-14-2.

Lee T, Komiya T, Watanabe K, Aizawa C, Hashimoto H.

Acta Virol. 1995 Jun;39(3):161-4.

PMID:
8578998
42.
43.

Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration.

Asanuma H, Koide F, Suzuki Y, Nagamine T, Aizawa C, Kurata T, Tamura S.

Vaccine. 1995 Jan;13(1):3-5.

PMID:
7762274
44.

Molecular cloning and sequence determination of the peplomer protein gene of feline infectious peritonitis virus type I.

Motokawa K, Hohdatsu T, Aizawa C, Koyama H, Hashimoto H.

Arch Virol. 1995;140(3):469-80.

PMID:
7733820
45.

Effects of cholera toxin adjuvant on IgE antibody response to orally or nasally administered ovalbumin.

Tamura S, Shoji Y, Hasiguchi K, Aizawa C, Kurata T.

Vaccine. 1994 Oct;12(13):1238-40.

PMID:
7839730
46.

Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice.

Tamura S, Asanuma H, Ito Y, Yoshizawa K, Nagamine T, Aizawa C, Kurata T.

Vaccine. 1994 Mar;12(4):310-6.

PMID:
8178552
47.

Permeable type I collagen membrane promotes glomerular epithelial cell growth in culture.

Nosaka K, Nishi T, Imaki H, Suzuki K, Kuwata S, Noiri E, Aizawa C, Kurokawa K.

Kidney Int. 1993 Feb;43(2):470-8. No abstract available.

48.

Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit.

Tamura S, Ito Y, Asanuma H, Hirabayashi Y, Suzuki Y, Nagamine T, Aizawa C, Kurata T.

J Immunol. 1992 Aug 1;149(3):981-8.

PMID:
1634780
49.

Effects of atrial natriuretic peptide on glycerol induced acute renal failure in the rat.

Seki G, Suzuki K, Nonaka T, Nosaka K, Taniguchi S, Aizawa C, Kurokawa K.

Jpn Heart J. 1992 May;33(3):383-93.

PMID:
1387917
50.

Supplemental Content

Loading ...
Support Center